title: Hepatoblastoma presenting with focal nodular hyperplasia after treatment of neuroblastoma.
abstract: Focal nodular hyperplasia (FNH) is a benign, poorly understood hepatic tumor that is rare in children. Although there is no evidence for malignant degeneration, FNH can occur adjacent to a malignancy. Here, the case of a 4-year-old boy with a hepatic mass and history of stage IV neuroblastoma is presented. Initial imaging and core-needle biopsy were consistent with FNH. However, after left lateral segmentectomy, pathologic examination revealed a malignant tumor most consistent with small cell undifferentiated hepatoblastoma as well as 3 foci of FNH in the surrounding parenchyma.
authors.affiliation: Department of Surgery, Children's Hospital Boston, Harvard Medical School, Boston, MA 02115, USA.
authors.forename: Jordan R
authors.initials: JR
authors.lastname: Gutweiler
authors.forename: David C
authors.initials: DC
authors.lastname: Yu
authors.forename: Heung B
authors.initials: HB
authors.lastname: Kim
authors.forename: Harry P
authors.initials: HP
authors.lastname: Kozakewich
authors.forename: Karen J
authors.initials: KJ
authors.lastname: Marcus
authors.forename: Robert C
authors.initials: RC
authors.lastname: Shamberger
authors.forename: Christopher B
authors.initials: CB
authors.lastname: Weldon
mesh_terms: D000310:Adrenal Gland Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D016190:Carboplatin / Q000008:administration & dosage; D002675:Child, Preschool; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005472:Fluorouracil / Q000008:administration & dosage; D020518:Focal Nodular Hyperplasia / Q000209:etiology*; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006498:Hepatectomy; D018197:Hepatoblastoma / Q000150:complications / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000601:surgery; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D007074:Immunoglobulin G / Q000627:therapeutic use; D033162:Incidental Findings; D008113:Liver Neoplasms / Q000150:complications / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000601:surgery; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D015080:Mesna / Q000008:administration & dosage; D009381:Neoplasms, Radiation-Induced / Q000209:etiology; D016609:Neoplasms, Second Primary / Q000150:complications / Q000175:diagnosis* / Q000473:pathology; D009447:Neuroblastoma / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects; D014057:Tomography, X-Ray Computed; D014750:Vincristine / Q000008:administration & dosage
chemical_list: C419226:3F8 antibody; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007074:Immunoglobulin G; D016179:Granulocyte Colony-Stimulating Factor; D014750:Vincristine; D005047:Etoposide; D003520:Cyclophosphamide; D016190:Carboplatin; D015080:Mesna; D002945:Cisplatin; D008558:Melphalan; D005472:Fluorouracil; D007069:Ifosfamide